Literature DB >> 23529718

[Modern antituberculosis treatment].

T Schaberg1, T Bauer, R Loddenkemper.   

Abstract

Based on estimates from the World Health Organization (WHO), there were 8.7 million new cases of tuberculosis (TB) and 1.4 million deaths globally in 2011. In Germany, TB has become a rare disease (incidence 5.3/100,000). Therefore, experience regarding the management and treatment of TB patients is decreasing. In this review, standard therapy of TB and the drugs administered are described. Prior to initiation of therapy, a thorough patient history must be taken to evaluate the risk factors for a drug-resistant TB. In addition, bacterial confirmation via microscopic and culture analyses and phenotypic drug susceptibility testing are also recommended. Treatment of TB is always based on combined antibiotic therapy. The selection of the drugs is determined by the resistance status of the strains. For detailed recommendations refer to the current recommendations of the German Central Committee against Tuberculosis e. V. (DZK) and the German Respiratory Society (DGP).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529718     DOI: 10.1007/s00108-013-3244-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  6 in total

Review 1.  Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease.

Authors:  Heather Milburn; Neil Ashman; Peter Davies; Sarah Doffman; Francis Drobniewski; Saye Khoo; Peter Ormerod; Marlies Ostermann; Catherine Snelson
Journal:  Thorax       Date:  2010-06       Impact factor: 9.139

2.  Tuberculosis: cost of illness in Germany.

Authors:  Roland Diel; Stefan Rutz; Stefanie Castell; Tom Schaberg
Journal:  Eur Respir J       Date:  2012-01-20       Impact factor: 16.671

3.  WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

Authors:  D Falzon; E Jaramillo; H J Schünemann; M Arentz; M Bauer; J Bayona; L Blanc; J A Caminero; C L Daley; C Duncombe; C Fitzpatrick; A Gebhard; H Getahun; M Henkens; T H Holtz; J Keravec; S Keshavjee; A J Khan; R Kulier; V Leimane; C Lienhardt; C Lu; A Mariandyshev; G B Migliori; F Mirzayev; C D Mitnick; P Nunn; G Nwagboniwe; O Oxlade; D Palmero; P Pavlinac; M I Quelapio; M C Raviglione; M L Rich; S Royce; S Rüsch-Gerdes; A Salakaia; R Sarin; D Sculier; F Varaine; M Vitoria; J L Walson; F Wares; K Weyer; R A White; M Zignol
Journal:  Eur Respir J       Date:  2011-08-04       Impact factor: 16.671

Review 4.  New drugs for the treatment of tuberculosis: hope and reality.

Authors:  J H Grosset; T G Singer; W R Bishai
Journal:  Int J Tuberc Lung Dis       Date:  2012-08       Impact factor: 2.373

5.  [Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)].

Authors:  T Schaberg; T Bauer; S Castell; K Dalhoff; A Detjen; R Diel; U Greinert; B Hauer; C Lange; K Magdorf; R Loddenkemper
Journal:  Pneumologie       Date:  2012-02-10

6.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.

Authors:  Dennis Falzon; Neel Gandhi; Giovanni B Migliori; Giovanni Sotgiu; Helen S Cox; Timothy H Holtz; Maria-Graciela Hollm-Delgado; Salmaan Keshavjee; Kathryn DeRiemer; Rosella Centis; Lia D'Ambrosio; Christoph G Lange; Melissa Bauer; Dick Menzies
Journal:  Eur Respir J       Date:  2012-10-25       Impact factor: 16.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.